In attempts to translate these findings into the clinical setting, NK cell activation by HDC/LD-IL-2 was assessed in serial blood samples of AML patients in CR who received HDC/LD-IL-2 in a phase 4 trial. The gene discussed is IL2; the disease is acute myeloid leukemia.